TD Cowen analyst Brendan Smith maintained a Buy rating on BioLife Solutions (BLFS – Research Report) today. The company’s shares closed today at $27.26.
According to TipRanks, Smith is a 3-star analyst with an average return of 2.2% and a 49.02% success rate. Smith covers the Healthcare sector, focusing on stocks such as BioLife Solutions, Twist Bioscience, and Halozyme.
Currently, the analyst consensus on BioLife Solutions is a Strong Buy with an average price target of $30.20.
Based on BioLife Solutions’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $30.57 million and a GAAP net loss of $1.7 million. In comparison, last year the company earned a revenue of $33.33 million and had a GAAP net loss of $29.13 million
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
BioLife Solutions (BLFS) Company Description:
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
Read More on BLFS:
- BioLife Solutions Strengthens Board with Tony J. Hunt Appointment
- Azenta upgraded to Overweight, named new ‘Best Idea’ at Stephens
- BioLife Solutions appoints Hunt to board of directors
- BioLife Solutions price target raised to $33 from $30 at KeyBanc
- BioLife Solutions price target lowered to $27 from $29 at H.C. Wainwright
